Press Release
CGBio’s HA filler “AiLEENE” enters Australia and New Zealand for the first time… Signs an $30 million export deal

▲ CGBio’s HA filler “AiLEENE” enters Australia and New Zealand for the first time… Signs an $30 million export deal

CGBio’s HA filler “AiLEENE” signals its entry into the massive Oceania market
Following the recent export deal for the HA filler Giselleligne, the company is on a roll.
Leveraging its know-how from successful entries into 25 countries worldwide, the company plans to actively expand its marketing efforts

Korea’s bio-regenerative medical company CGBio announced on the 23rd that it has signed a deal to export its hyaluronic acid (HA) filler “AiLEENE” to Australia and New Zealand worth US$30 million. Through this contract, CGBio is expected to generate sales of around $7.7 million with the single product alone, as it expands into the Oceania beauty and cosmetic surgery market.

In addition, CGBio recently signed an export contract with Chinese medical device distributor Shanghai Feiting Trading to supply HA fillers Giselleligne Universal and Giselleligne Signature 2 for a scale of 470 billion won ($359 million) over three years, signaling its entry into the massive Chinese filler market.

Amore Aesthetics, which signed the export agreement with CGBio, is a franchise company affiliated with Haus Cosmetics, a leading medical spa brand in Australia and New Zealand with a network of about 300 locations in the Oceania region, enabling immediate sales and product distribution.

The size of the filler market in Australia and New Zealand is estimated at around $2.8 billion as of 2021, and CGBio’s sales and distribution deal is seen as a signal that it is entering the substantial Oceania market.

AiLEENE is the world’s first multi-layered phasic filler that combines the advantages of highly viscous monophasic fillers and highly elastic biphasic fillers. It has the characteristic of minimum swelling after injection and a visual analog scale score that is about half that of other products. In addition, the crosslinking ratio (degree of modification), which indicates the degree of transformation from natural hyaluronic acid, is significantly low at around 2%, making it a safe filler that is close to its natural state. It is also easy to modify during the procedure and easy to remove after the procedure.

AiLEENE filler comes in three types according to the degree of viscosity and elasticity and product selection is possible depending on the treatment area. “Vol#1” is suitable for soft areas such as the forehead and under the eyes, “Vol#2” is good for areas that require volume and persistence such as nasolabial folds and forehead, and “Vol#3” with high viscosity and elasticity is right for areas that require volume emphasis such as the nose, forehead and chin.

CGBio also operates a high-level aesthetic medical education program for overseas medical professionals, including global webinars and CADAVER workshops, continuously and systematically. Through this, medical professionals acquire advanced techniques and ultimately provide safer and more effective treatment to their patients.

Hyun Seung Yu, the CEO of CGBio, said, “As this is Aileen’s first foray into the Australian and New Zealand market, we will spare no effort in providing active support to ensure successful regional distribution,” adding, “Based on this achievement, we will continue to enhance our competitiveness in the Oceania region and explore overseas markets, solidifying our position as a global regenerative medicine specialist.”

▲ AiLEENE Product